1-甲基-3-(羟基乙基)氮杂环丁烷 | 1363381-66-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氮杂环丁烷
• 中文名称: 1-甲基-3-(羟基乙基)氮杂环丁烷
• 英文名称: 2-(1-Methylazetidin-3-yl)ethanol
• CAS: 1363381-66-1
• 化学式: C₆H₁₃NO
• mdl: MFCD21641987
• 分子量: 115.17
• InChiKey: XUCLCYHNWRAQJA-UHFFFAOYSA-N

物化性质

• 沸点：
  162.2±13.0 °C(Predicted)
• 密度：
  0.983±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  23.5
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS<br/>[FR] COMPOSÉS 1H-PYRAZOLO [4,3-D]PYRIMIDINE EN TANT QU'AGONISTES DU RÉCEPTEUR 7 DE TYPE TOLL (TLR7)
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2021154661A1

  公开（公告）日：2021-08-05

  Compounds according to formula I are useful as agonists of Toll-like receptor 7 (TLR7). Such compounds can be used in cancer treatment, especially in combination with an anti-cancer immunotherapy agent, or as a vaccine adjuvant.

  根据公式I的化合物可作为Toll样受体7（TLR7）的激动剂。这些化合物可用于癌症治疗，特别是与抗癌免疫疗法药物联合使用，或作为疫苗佐剂。
• Substituted pyrazolo[1,5-a]pyridine compounds as RET kinase inhibitors
  申请人：Array BioPharma, Inc.

  公开号：US10137124B2

  公开（公告）日：2018-11-27

  Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.

  本文提供了公式I的化合物，其立体异构体和药学上可接受的盐或溶剂，其中A、B、X1、X2、X3、X4、环D和E在规范中给出的含义，它们是RET激酶的抑制剂，并可用于治疗和预防可通过RET激酶抑制剂治疗的疾病，包括RET相关的疾病和障碍。
• Triazole compounds and methods of making and using the same
  申请人：Bhattacharjee Ashoke

  公开号：US20100016956A1

  公开（公告）日：2010-01-21

  The present invention provides triazole macrocyclic compounds useful as therapeutic agents. More particularly, these compounds are useful as anti-infective, anti-proliferative, anti-inflammatory, and prokinetic agents. The compounds have the following structure: wherein T is the macrocyclic part.

  本发明提供了三唑大环化合物，作为治疗剂非常有用。更具体地说，这些化合物可用作抗感染、抗增殖、抗炎和促动力剂。化合物具有以下结构：其中T是大环部分。
• Pyrrolopyrimidine Derivatives Substituted with Cyclic Amino Group
  申请人：NAKAZATO Atsuro

  公开号：US20080287397A1

  公开（公告）日：2008-11-20

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，作为治疗或预防与CRF有关的疾病的药物，例如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等。这个问题可以通过下式[I]所表示的带有环状氨基基团的吡咯吡嘧啶或吡咯吡啶衍生物来解决，其具有高亲和力，对CRF受体有效，并且对与CRF有关的疾病也有效。
• PYRROLOPYRIDINE DERIVATIVES SUBSTITUTED WITH CYCLIC AMINO GROUP
  申请人：NAKAZATO Atsuro

  公开号：US20110130364A1

  公开（公告）日：2011-06-02

  An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

  本发明的目的是提供一种CRF受体拮抗剂，该拮抗剂作为治疗或预防CRF参与的疾病的药物，如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等方面有效。这个问题可以通过一种代表式[I]下的带有环状氨基基团的吡咯吡咪啉或吡咯吡啶衍生物来解决，该衍生物对CRF受体具有高亲和力，并对CRF参与的疾病有效。